Researchers develop a plug-and-play test that enables real-time monitoring of engineered T-cells, improving the precision and ...

A novel test enables real-time monitoring of T cells that have been engineered to fight cancer, after re-introduction into the body of a cancer patient. This simple and innovative test provides ...

A new drug strategy that regulates the tumor immune microenvironment may transform a tumor that resists immunotherapy into a susceptible one, according to a new study.

Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate ...

I have been a cancer doctor for 40 years and have seen our treatments evolve to embrace precision medicine and immunotherapy ... dealing with potentially deadly side effects. One prominent example ...

Trials with mice in whom the researchers implanted human glioblastoma cells have already shown that the treatment is very ...

A breast cancer vaccine could be closer to reality, according to Cleveland Clinic, as its researchers have announced some ...

Severe treatment-related side effects were more frequent in the investigational ... Anti-TIGIT antibody: a type of ...

As of September 30, 2024, the Company had approximately $32.4 million in cash and cash equivalents compared with $48.5 ...

Researchers at UC San Francisco developed SNIPRs, sensors that activate engineered cells only in the tumor environment, ...

An estimated 4,500 prescriptions have been filled in 2024 so far, Iwatsubo said. About 80 percent of patients have mild cognitive impairment, the rest have mild dementia. Most are in their 70s, and ...

Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced the completion of the dosing and initial follow-up period for ...